Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000734395 | SCV000862534 | uncertain significance | not provided | 2018-07-18 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000734395 | SCV001816303 | uncertain significance | not provided | 2023-07-31 | criteria provided, single submitter | clinical testing | Has not been previously published as pathogenic or benign to our knowledge; Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function |
Fulgent Genetics, |
RCV002507308 | SCV002814454 | uncertain significance | Ehlers-Danlos syndrome due to tenascin-X deficiency; Vesicoureteral reflux 8 | 2021-08-11 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV003303224 | SCV003998927 | uncertain significance | Cardiovascular phenotype | 2024-10-01 | criteria provided, single submitter | clinical testing | The c.8186A>G (p.E2729G) alteration is located in exon 24 (coding exon 23) of the TNXB gene. This alteration results from a A to G substitution at nucleotide position 8186, causing the glutamic acid (E) at amino acid position 2729 to be replaced by a glycine (G). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |